Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Gsk exchanges : Amex save search
Oral Biologics & Biosimilars Global Market Report 2022: Drive to Create Insulin Biosimilars Presents Opportunities
Published: 2022-10-14 (Crawled : 12:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 6.95%
H: 0.0%
C: 0.0%
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: 1.95%
H: 1.5%
C: 1.5%
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: 0.03%
H: 0.35%
C: -1.01%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: 0.59%
H: 0.66%
C: -0.39%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 2.74%
H: 0.0%
C: 0.0%
ENTX | $2.07 -6.76% -7.25% 160K
|
Health Technology
|
| O: 1.06%
H: 0.01%
C: -4.53%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: 1.22%
H: 0.52%
C: -2.21%
RVP P | $1.09 1.87% 0.0% 25K
|
Health Technology
|
| O: -1.55%
H: 8.42%
C: 5.26%
global report insulin market
Head and Neck Cancer Market worth $ 9.07 Billion by 2030 - Exclusive Report by InsightAce Analytic
Published: 2022-03-23 (Crawled : 11:00) - prnewswire.com
GLAXF | News | $19.54 -14.18% 2.6K
|
Health Technology
|
| O: 3.81%
H: 0.0%
C: -0.44%
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: -4.55%
H: 6.28%
C: 6.28%
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -1.94%
H: 0.0%
C: 0.0%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -0.6%
H: 0.0%
C: 0.0%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: -0.87%
H: 0.0%
C: 0.0%
BMY | $48.86 -0.27% 0.0% 16M
|
Health Technology
|
| O: -0.55%
H: 0.0%
C: 0.0%
MGNX | $15.7 -3.27% -3.38% 520K
|
Health Technology
|
| O: -1.31%
H: 3.88%
C: -0.67%
KURA | News | $18.76 0.16% 0.16% 670K
|
Health Technology
|
| O: -1.34%
H: 0.12%
C: -2.6%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.04%
H: 0.08%
C: -1.26%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: -0.31%
H: 1.85%
C: 1.55%
ADXS | $0.54 12.48% 950
|
Health Technology
|
| O: -1.64%
H: 8.33%
C: 0.0%
CVM | $1.46 -0.68% 0.0% 76K
|
Health Technology
|
| O: -0.92%
H: 2.31%
C: -3.47%
report cancer market
iBio Appoints William D. Clark to its Board of Directors
Published: 2021-08-26 (Crawled : 16:00) - globenewswire.com
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: -0.19%
H: 0.18%
C: -0.19%
VNDA | $4.57 -1.3% -1.31% 1.2M
|
Health Technology
|
| O: -0.06%
H: 0.78%
C: -0.54%
GNCA | $0.051
|
Health Technology
|
| O: 0.54%
H: 2.42%
C: -1.61%
IBIO | $1.9 0.0% 99K
|
Health Technology
|
| O: 0.79%
H: 3.15%
C: -3.94%
Global Oral Biologics & Biosimilar Drugs Markets 2021-2030: Asthma, Crohn's Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis
Published: 2021-08-06 (Crawled : 15:00) - prnewswire.com
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: -4.5%
H: 0.0%
C: 0.0%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: -0.95%
H: 0.23%
C: -0.3%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.26%
H: 0.0%
C: 0.0%
ENTX | $2.07 -6.76% -7.25% 160K
|
Health Technology
|
| O: 2.23%
H: 0.0%
C: -1.39%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: -2.02%
H: 0.09%
C: -1.38%
RVP P | $1.09 1.87% 0.0% 25K
|
Health Technology
|
| O: -0.08%
H: 1.82%
C: 0.87%
multiple sclerosis disease diabetes drug sclerosis psoriasis biosimilar
Gainers vs Losers
| 65% | 35% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 210M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.